Purpose

To evaluate the efficacy of thermoelectric warming therapy (MiBoFlo) in improving patient symptoms with standardized questionnaires and objective signs of meibomian gland dysfunction (MGD), which is an important underlying treatable factor in dry eye disease (DED), such as ocular surface staining, tear quality, and meibomian gland morphology. Multivariate analysis to identify predictors for the improvement in Ocular Surface Disease Index (OSDI) was also performed.

Design

Retrospective before-and-after study.

Methods

A total of 203 eyes of 102 patients with DED were treated with MiBoFlo at the dry eye center. The OSDI and Standard Patient Evaluation of Eye Dryness (SPEED) questionnaires, best-corrected visual acuity, tear osmolarity, tear film breakup time (TBUT), corneal and conjunctival staining, meibography, number of glands expressing liquid, and quality of the improved meibum were assessed before and 6 months after MiBoFlo. Exclusion criteria included active ocular inflammation.

Results

Dry eye symptoms improved in the population, with both SPEED and OSDI lowering of dry eye symptoms by approximately 35% (P < .001) at month 6. Significant improvements in lissamine green conjunctival staining, corneal fluorescein staining, TBUT, osmolarity, and secreting meibomian glands and meibum quality were also seen. Improvement was seen across all domains of the questionnaires and across all baseline parameters. Eyes with blepharitis and autoimmune disease improved less than average. No complications or adverse events occurred.

Conclusions

MiBoFlo treatments produced clinical and statistically significant improvements in the signs and symptoms of MGD, irrespective of underlying ocular conditions. This improvement was sustained for the 6-month period of observation after initiating the treatment.

中文翻译：

---

热电加温疗法治疗睑板腺功能障碍的效果

目的

使用标准化问卷和睑板腺功能障碍 (MGD) 的客观体征评估热电加温疗法 (MiBoFlo) 在改善患者症状方面的功效，睑板腺功能障碍 (MGD) 是干眼病 (DED) 的重要潜在可治疗因素，例如眼表染色，泪液质量和睑板腺形态。还进行了多变量分析以确定眼表疾病指数（OSDI）改善的预测因子。

设计

回顾性前后研究。

方法

102 名 DED 患者的 203 只眼在干眼中心接受 MiBoFlo 治疗。OSDI 和标准患者眼干评估 (SPEED) 问卷、最佳矫正视力、泪液渗透压、泪膜破裂时间 (TBUT)、角膜和结膜染色、睑板描记术、表达液体的腺体数量和改善睑脂的质量在 MiBoFlo 之前和之后 6 个月进行了评估。排除标准包括活动性眼部炎症。

结果

人群中的干眼症状有所改善，SPEED 和 OSDI 在第 6 个月将干眼症状降低了约 35% ( P < .001)。丽丝胺绿结膜染色、角膜荧光素染色、TBUT、渗透压和分泌显着改善还看到了睑板腺和睑脂质量。在问卷的所有领域和所有基线参数中都看到了改进。患有睑缘炎和自身免疫性疾病的眼睛改善低于平均水平。没有发生并发症或不良事件。

结论

MiBoFlo 治疗在 MGD 的体征和症状方面产生了临床和统计学上显着的改善，无论潜在的眼部状况如何。这种改善在开始治疗后的 6 个月观察期内持续存在。